The phase 3 clinical trial of CAN-2409 in intermediate-to-high-risk, localized prostate cancer met its primary endpoint, by demonstrating statistically significant improvement in disease-free survival ...

The TIME is a dynamic network composed of cancer cells, immune cells, and stromal components. During the early stages of tumorigenesis, the TIME ...

Prostate cancer vaccines, including dendritic and peptide types, offer hope for improved treatments, but face hurdles in ...

Data from the ongoing Phase 2 of EO4010 demonstrate tumor target specific immune responses and objective tumor responses, including in liver mets, in patients with previously treated microsatellite ...

*仅供医学专业人士阅读参考前两天奇点糕才提到，对免疫治疗维持“绝对防御”的卵巢癌，可以通过分泌白介素-4（IL-4）调控巨噬细胞，构建免疫抑制性微环境，如果要给这种行为定性一下，大概可以算是卵巢癌对免疫治疗不敏感的“内因”。既然有内因，相对就一定会有 ...

About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing form of lymphoma, will see their disease advance or recur following treatment. Seeking a new treatment strategy ...

Pilatus Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) ...